Back Home About Us

Atazanavir (Reyataz) Label Changes Cover Drug Interactions, Kidney Impairment

The U.S. Food and Drug Administration this week announced revisions to the package insert for the protease inhibitor atazanavir (Reyataz), reflecting new information about administration with food, interaction with several drugs, and use by patients with impaired kidney function.

Read more:

Monoclonal Antibody CCR5 Inhibitor PRO 140 Produces Long-lasting HIV Suppression in Single-dose Study

In order to enter human CD4 T-cells, HIV must bind to both the CD4 receptor on the cell surface and 1 of 2 co-receptors, CCR5 or CXCR4. If the virus cannot attach to a co-receptor, it cannot infect new cells. The first oral CCR5 antagonist, maraviroc (Selzentry) was recently approved, and another such agent, vicriviroc, has shown promising results in clinical trials.

Read more:

SMART Data Confirm Risk of CD4-guided Treatment Interruptions

Interruption of antiretroviral therapy is a potentially hazardous strategy associated with an increased risk of disease progression or death, according to data from the large international SMART (Strategies for Management of Antiretroviral Therapy) study.

Read more:

Insulin Resistance and Liver Injury in Patients with Hepatitis C Are Not Associated with Virus-Specific Changes in Adipocytokines

There is a growing body of evidence linking hepatitis C virus (HCV) infection with metabolic abnormalities including type 2 diabetes mellitus. However, the role of adipocytokines in HCV-associated insulin resistance is not yet clear.

Read more:

AASLD 2006: Liver Transplantation in HIV Positive Patients

The Thomas E. Starzl Transplant Surgery State-of the-Art Lecture at this year’s American Association for the Study of Liver Diseases (AASLD) annual meeting was devoted to the outcomes following solid organ transplantation in HIV-infected recipients. The speaker, Peter G. Stock, MD, from the University of California at San Francisco, gave a very good update on the topic.

alt

Read more:

Adult Circumcision Reduces Men's Risk of HIV Infection

Adult male circumcision is emerging as a potentially important public health measure for reducing the risk of HIV transmission to men during heterosexual sex. A previous study in South Africa showed that elective circumcision reduced men's HIV infection rate by 61% (Auvert et al 2005).

Read more:

AIDS 2006: TNX-355 Produces Significant Reduction in HIV Viral Load at 48 Weeks

Data on several investigational anti-HIV drug candidates were presented at the XVI International AIDS Conference last week in Toronto, including the latest results from a study of Tanox’s investigational monoclonal antibody, TNX-355. TNX-355 is a recombinant human antibody that binds to domain 2 of the CD4 receptor, thereby blocking the entry of HIV into host cells. 

alt

Read more: